• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » NxStage Medical tops Q4, 2013 estimates

NxStage Medical tops Q4, 2013 estimates

February 27, 2014 By Brad Perriello

NxStage Medical tops Q4, 2013 estimates

NxStage Medical (NSDQ:NXTM) shares rose today after the medical device company said it just beat estimates with its results for the 4th quarter and last year.

Lawrence, Mass.-based NxStage, which makes the System 1 home hemodialysis system, posted losses of -$5.2 million, or -8¢ per share, on sales of $69.5 million for the 3 months ended Dec. 31, 2013. That represents more than double the losses posted in Q4 2012, on a 6.8% sales gain.

The numbers topped the consensus earnings-per-share estimate on Wall Street by a penny and beat both NxStage’s own sales forecast and the consensus view.

Full-year losses were -$18.6 million, or -31¢ per share, on sales of $263.4 million, for a 22.5% increase in losses on sales growth of 8.8% over 2012. The Street was looking for losses per share of 32¢. The annual results also topped NxStage’s prior forecast.

"At the start of 2013, we placed a major focus on growth and investment to take advantage of the significant opportunity in front of us and create long term shareholder value," founder & CEO Jeffrey Burbank said in prepared remarks. "We made great progress across a number of key areas as evidenced by early positive momentum with our direct to patient marketing and solid execution on our innovation pipeline."

NxStage said it expects to log losses of $6.5 million to $7.5 million , or -11¢ to -12¢ per share, on sales of $69.5 million to $70.5 million during the 1st quarter. Full-year losses are slated to range between -$23.0 million and -$27.0 million, or -37¢ to -44¢ per share, on sales of $283 million to $288 million.

"Similar to this past year, 2014 will be focused on growth and investment. We remain confident in the strength of our near-term initiatives to achieve our target of 15% annual growth in the Home and are continuing to invest significantly in long-term initiatives to increase patient access to our therapies and accelerate adoption. These initiatives include another robust innovation pipeline with peritoneal dialysis and next generation products, and expanded market development activities with a cadence of one to three additional NxStage Kidney Care centers each quarter in 2014, leading to a total of approximately 10 to 15 centers by the end of this year," Burbank said.

NXTM shares were trading at $13.52 apiece as of about 11:45 a.m. today, down 1.8%.

Filed Under: MassDevice Earnings Roundup, News Well Tagged With: 2013, Dialysis, NxStage Medical Inc., Q4

More recent news

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy